Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 925-935

  Oh, Jong Ryool ^a   Seo, Ji Hyoung ^b   Chong, Ari ^a   Min, Jung Joon ^a   Song, Ho Chun ^a   Kim, Young Chul ^c   Bom, Hee Seung ^a  

^a Chonnam National University Medical School   (South Korea)

^b Daegu Fatima Hospital   (South Korea)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

18F FDG; PET CT; Prognosis; Small cell lung cancer; Whole body metabolic tumour volume

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; LACTATE DEHYDROGENASE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREMEDICATION; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; REVIEW; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; WHOLE BODY METABOLIC TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84862671653     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2059-7     Document Type: Review

References (25)

1. GR Simon H Wagner American College of Chest Physicians 2003 Small cell lung cancer Chest 123 259S 271S 12527584 10.1378/chest.123.1-suppl.259S
2. E Vallières FA Shepherd J Crowley P Van Houtte PE Postmus D Carney, et al. 2009 The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer J Thorac Oncol 4 1049 1059 19652623 10.1097/JTO.0b013e3181b27799
3. JD Bradley F Dehdashti MA Mintun R Govindan K Trinkaus BA Siegel 2004 Positron emission tomography in limited-stage small-cell lung cancer: a prospective study J Clin Oncol 22 3248 3254 15310768 10.1200/JCO.2004.11.089
4. I Brink T Schumacher M Mix S Ruhland E Stoelben W Digel, et al. 2004 Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol Imaging 31 1614 1620 15258700 10.1007/s00259-004-1606-x 1:STN:280:DC%2BD2cngvVKkuw%3D%3D
5. BM Fischer J Mortensen SW Langer A Loft AK Berthelsen BI Petersen, et al. 2007 A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis Ann Oncol 18 338 345 17060487 10.1093/annonc/mdl374 1:STN:280:DC%2BD2s%2FotlagsQ%3D%3D
6. EM Kamel D Zwahlen MT Wyss KD Stumpe GK von Schulthess HC Steinert 2003 Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer J Nucl Med 44 1911 1917 14660716
7. YS Seo SY Kwon SY Jeong HC Song JJ Min KS Kim, et al. 2007 Correlation of pre-treatment FDG uptake to therapeutic response and relapse in patients with small cell lung cancer Nucl Med Mol Imaging 41 538 545
8. MK Chung HS Jeong SG Park JY Jang YI Son JY Choi, et al. 2009 Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer Clin Cancer Res 15 5861 5868 19737951 10.1158/1078-0432.CCR-08-3290 1:CAS:528:DC%2BD1MXhtFars7rM
9. SH Hyun JY Choi YM Shim K Kim SJ Lee YS Cho, et al. 2010 Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma Ann Surg Oncol 17 115 122 19826877 10.1245/s10434-009-0719-7
10. H Yan R Wang F Zhao K Zhu S Jiang W Zhao, et al. 2011 Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy Acta Radiol 52 646 650 21508201 10.1258/ar.2011.100462
11. D Zhu T Ma Z Niu J Zheng A Han S Zhao, et al. 2011 Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer Lung Cancer 73 332 337 21292341 10.1016/j.lungcan.2011.01.007
12. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on (18)F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39:27-38. doi: 10.1007/s00259-011-1934-6.
13. RA Stahel R Ginsberg K Havemann FR Hirsch DC Ihde J Jassem, et al. 1989 Staging and prognostic factors in small cell lung cancer: a consensus report Lung Cancer 5 119 126 10.1016/0169-5002(89)90156-6
14. FA Shepherd J Crowley P Van Houtte PE Postmus D Carney K Chansky, et al. 2007 The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 2 1067 1077 18090577 10.1097/JTO.0b013e31815bdc0d
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al., editors. AJCC cancer staging manual. Chicago: Springer; 2010. p. 253-70.
16. YJ Lee A Cho BC Cho M Yun SK Kim J Chang, et al. 2009 High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer Clin Cancer Res 15 2426 2432 19318478 10.1158/1078-0432.CCR-08-2258 1:CAS:528:DC%2BD1MXjvVWksrg%3D
17. NA Bayman H Sheikh B Kularatne P Lorigan F Blackhall N Thatcher, et al. 2009 Radiotherapy for small-cell lung cancer-where are we heading? Lung Cancer 63 307 314 18676057 10.1016/j.lungcan.2008.06.013 1:STN:280: DC%2BD1M7itlWkuw%3D%3D
18. BJ Slotman 2010 Radiotherapy for extensive stage small cell lung cancer Front Radiat Ther Oncol 42 187 192 19955806 10.1159/000262475 1:STN:280:DC%2BC3c7lsleguw%3D%3D
19. HH Chung JW Kim KH Han JS Eo KW Kang NH Park, et al. 2011 Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer Gynecol Oncol 120 270 274 21109300 10.1016/j.ygyno.2010.11.002
20. HY Lee SH Hyun KS Lee BT Kim J Kim YM Shim, et al. 2010 Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications Ann Surg Oncol 17 2787 2794 20461469 10.1245/s10434-010-1107-z
21. RW Byhardt A Hartz JA Libnoch R Hansen JD Cox 1986 Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL) Int J Radiat Oncol Biol Phys 12 771 777 3011712 10.1016/0360-3016(86)90035-0 1:STN:280:DyaL283itlCgsw%3D%3D
22. JJ Ludbrook PT Truong MV MacNeil M Lesperance A Webber H Joe, et al. 2003 Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis Int J Radiat Oncol Biol Phys 55 1321 1330 12654444 10.1016/S0360-3016(02)04576-5
23. M Paesmans JP Sculier J Lecomte J Thiriaux P Libert R Sergysels, et al. 2000 Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years Cancer 89 523 533 10931451 10.1002/1097- 0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6 1:STN:280: DC%2BD3cvgt1aktQ%3D%3D
24. C Greco K Rosenzweig GL Cascini O Tamburrini 2007 Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC) Lung Cancer 57 125 134 17478008 10.1016/j.lungcan.2007.03.020
25. G Lucignani G Paganelli E Bombardieri 2004 The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective Nucl Med Commun 25 651 656 15208491 10.1097/01.mnm.0000134329.30912.49 1:STN:280:DC%2BD2cznslOnsQ%3D%3D